Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
n-benzyl-4-[4-(3-chlorophenyl)-1h-pyrazol-3-yl]-1h-pyrrole-2-carboxamide
- Development stage
- Unknown
- Lead developer
- Vertex
- Modality
- Small Molecules
01
Overview
N-benzyl-4-[4-(3-chlorophenyl)-1h-pyrazol-3-yl]-1h-pyrrole-2-carboxamide is a small molecule compound belonging to the phenylpyrazole class. It has been studied as an inhibitor of mitogen-activated protein kinases, particularly ERK (extracellular signal-regulated kinase) and JNK (c-Jun N-terminal kinase), which are key components of the Ras/Raf/MEK/ERK signaling pathway implicated in cancer cell proliferation and survival. The compound was developed as part of structure-guided optimization efforts for selective kinase inhibitors, with demonstrated binding to both ERK2 and JNK3 in crystallographic studies[7][8]. No clinical trials or regulatory approvals have been reported for this specific compound.
- Other names
- N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDEN-Benzyl-4-[4-(3-chlorophenyl)-1H-pyrazol-5-yl]-1H-pyrrole-2-carboxamide (note: this is a common mislabeling due to pyrazole numbering)Pyrrole Carboxamide Analog 5g[5]CID 135449325[6]
02
Targets
JNK (Mitogen-activated protein kinase kinase kinase family)MAPK3 (Mitogen-activated protein kinase 1)
Beyond the preview
Go deeper on n-benzyl-4-[4-(3-chlorophenyl)-1h-pyrazol-3-yl]-1h-pyrrole-2-carboxamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on n-benzyl-4-[4-(3-chlorophenyl)-1h-pyrazol-3-yl]-1h-pyrrole-2-carboxamide.